CSI Market
Sign In | Register

Avenue Therapeutics Inc (ATXI) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access ATXI Annual Cash Flow →
This cash flow overview for Avenue Therapeutics Inc spans from Jun 30 2025 to Jun 30 2026, illustrating how cash generation and usage have shifted across recent reporting periods.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Jun 30 2026)
6 Months 		(Mar 31 2026) (Dec 31 2025) (Sep 30 2025) (Jun 30 2025)
Operating Activities
Income-1.39
Depreciation & amortization0.00
Amortization of Other Assets0.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets0.00
Share-based Compensation0.12
Income (Loss) from Equity Method Investments0.00
Fair Value Adjustment of Warrants0.00
Fair Value Adjustments Of Convertible Notes Payable-
Other Research And Development Expense-
Issuance Of Common Shares For Founders Agreement-
Common Stock Issuable For Founder Agreement-
Adjustments For Common Shares Issuable-
Issuance Of Stock For Licenses Acquired-
Research And Development License Acquried Expense-
Issuance Of Stock Under Founders Agreement-0.36
Increase Decrease In Accrued Licenses Acquired-
Increase Decrease In Deferred Financing Costs-
Common Stock Issued To Fortress Value0.76
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Receivables0.00
Increase (Decrease) in Accounts Payable and Accrued Liabilities0.00
Increase (Decrease) in Interest Payable, Net0.00
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets-0.04
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities0.39
Discontinued operations0.00
Net Cash flow from Operating Activities-0.91
Investing Activities
Capital Expenditures0.00
Sale of Capital Items0.00
Payments for (Proceeds from) Short-term Investments, Total0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Milestone Payment For Research And Development Licenses-
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments to Acquire Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Payments to Acquire in Process Research and Development0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities0.00
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.00
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.00
Issuance Of Common Stock Prefund Warrants And Warrants-
Payments Of Warrants Exercise Transaction Costs-1.21
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities0.00
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-0.91
Total Cash Flow-0.91
4 historic quarters locked

Sign in to unlock the full Avenue Therapeutics Inc cash flow history.

Sign In Create Free Account

About Avenue Therapeutics Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001437749-26-026372

Figures are derived from filed reports and may be restated. Historical data is subject to revision.